Cas12a(cpf1) crRNA
Accelerate precision gene editing with GenScript's custom synthetic crRNA for Cas12a(cpf1) projects.
Receive your quote directly from the manufacturer.
Custom synthetic CRISPR RNA (crRNA) for Cas12a-based gene editing, screening, and diagnostic applications. Our bespoke service offers extensive customization options and expert support to guide you through every step.
Easily design high-performance crRNA with our intelligent GenCRISPR gRNA Design Tool, which ranks guides based on on-target and off-target scores for optimal results.
De-risk your CRISPR pipeline with scalable cGMP guide RNA
Tuesday, April 8, 2025 – 16:00 BST / 17:00 CEST / 11:00 EDT / 08:00 PDT
Join us for an exclusive webinar with Dr. Pedro Teh as he explores how expert guide RNA (gRNA) manufacturing services can help accelerate your CRISPR-based therapeutic development in line with current good manufacturing practices (cGMP).
As a trusted partner in cell and gene therapy, GenScript provides high-quality, scalable, and regulatory-compliant gRNA for CRISPR systems including Cas9, Cas12a, prime editing, and base editing.
Discover how GenScript's cGMP synthesis capabilities and state-of-the-art production facility ensures a streamlined 30-day turnaround for clinical-grade gRNA, and see how comprehensive documentation support – including Drug Master Files (DMFs) – can facilitate smooth investigational new drug (IND) submissions and regulatory approvals.
Whether you're in early-stage research or preparing for clinical trials, this webinar will show you how GenScript's expertise in cGMP nucleic acid manufacturing, quality control, and regulatory support can help de-risk and accelerate your CRISPR therapeutic pipeline.
Key learning objectives:
- Learn about cGMP guide RNA manufacturing and quality control processes
- Explore a range of gene editing approaches that can be supported by cGMP gRNA services
- Understand how expert documentation support simplifies IND submissions and regulatory approvals
- Learn why procuring RUO to cGMP gRNA from a single vendor streamlines and de-risks the development process for CRISPR therapies
Who should attend?
Scientists and decision-makers from biopharma, biotech, and academic institutions using gene editing for discovery or preclinical research.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
